MedWatch

Zealand Pharma still on the rise

The biotech company Zealand Pharma presented a Q1 net surplus that was higher than in the same period last year. Turnover has also increased significantly.

Foto: Zealand Pharma/PR

With a net surplus of DKK 66 million and a turnover of 120 million the Danish biotech company Zealand Pharma was still on the rise in the first quarter of 2012. The numbers from the same period last year were DKK 44.9 million and a big, fat zero, respectively.

"During the first months of 2012, we have further strengthened our cash position alongside important progress for our pipeline of peptide drug candidates. Our partner, Sanofi, completed the global Phase III program, GetGoal, for lixisenatide (Lyxumia®) — now in the registration phase in Europe — with positive results from the GetGoal-P study supporting the intended use of this novel once-daily GLP-1 in the treatment of patients Type 2 diabetes,” says CEO David Solomon in a press release and continues:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier